At a glance
ClinicalIndex Comparison RecordN/ACompleted· 479 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database
In Brief
An observational study for Rheumatoid Arthritis. Completed, enrolled 479 participants across 1 site.
Detailed Summary
To address the objectives, a retrospective cohort design will be employed to evaluate patient characteristics, treatment patterns, medication effectiveness, and health care cost and utilization in RA patients newly initiating tofacitinib in combination with oral methotrexate (MTX)
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
Primary CompletionOct 2018
First PostedJun 2019
TodayJul 2026
First PostedJun 5, 2019
Enrollment StartMay 29, 2018
Primary CompletionOct 2, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.1 years ago